Hydrothermal Duodenal Mucosal Resurfacing

Disclosure Statement: A.D. Cherrington is scientific advisor/consultant to Biocon, Calibr, Eli Lilly and Company, Fractyl Laboratories, Inc, Hanmi, Islet Sciences, Merck & Co, Metavention, Novo Nordisk, NuSirt Biopharma, Profil Institute for Clinical Research, Inc, Sensulin, Thermalin Diabetes, Thetis Pharmaceuticals, vTv Therapeutics, ViaCyte, Viking, and Zafgen; receives research support from Merck & Co, Novo Nordisk, Silver Lake (1R43DK106944-01) and Galvanie; and has equity/stock options in Fractyl Laboratories, Inc, Metavention, Sensulin, LLC, Thetis Pharmaceuticals, and Zafgen. H. Rajagopalan is an employee of Fractyl Laboratories, Inc, and holds shares in the company. D. Maggs is an employee of Fractyl Laboratories, Inc, and holds shares in the company. J. Devière is a consultant for Boston Scientific, Olympus, and Cook Endoscopy and has equity in Endotools Therapeutics. a Molecular Physiology & Biophysics, Vanderbilt University School of Medicine, 704A/710 Robinson Research Building, 2200 Pierce Avenue, Nashville, TN 37232-0615, USA; b Fractyl Laboratories, Inc, 17 Hartwell Avenue, Lexington, MA 02421, USA; c Medical-Surgical Department of Gastroenterology, Hepatopancreatology and Digestive Oncology, Erasme Hospital, Université Libre de Bruxelles, Route de Lennik 808, Brussels 1070, Belgium * Corresponding author. E-mail address: [email protected]